Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Information
Welcome
Investor Fact Sheet
Investor Presentations
Media
Top 20 Shareholders
Shareholder Services
Investor FAQs
US Shareholders
Announcements & Reports
ASX Announcements
Publications
Annual Reports
Half Yearly Reports
Quarterly Reports
Research Reports
Contact Us
Contact Us
Email Alerts
Media
Recent Posts
Entitlement Offer to raise $4.27m
Proactive Interview with Dr Chris Burns
FDA clearance of Amplia's IND for pancreatic cancer trial in US
First patient dosed in phase 2a ACCENT trial
Investor Newsletter - December 2023
Archives
April 2024
February 2024
January 2024
December 2023
November 2023
October 2023
September 2023
August 2023
July 2023
June 2023
May 2023
April 2023
February 2023
January 2023
December 2022
November 2022
October 2022
September 2022
August 2022
July 2022
Categories
Company News
Media
Uncategorized
Videos
22 May 2023
Amplia receives grant to collaborate with CSIRO
Read More
09 May 2023
Enrolment of Cohort 3 of ACCENT Trial in Pancreatic Cancer Complete
Read More
26 Apr 2023
Quarterly Activities and Cash Flow Report - 31 March 2023
Read More
19 Apr 2023
First Patient Recruited to Cohort 3 of ACCENT Trial in Pancreatic Cancer
Read More
11 Apr 2023
Dose Escalation Approved in ACCENT Clinical Trial of AMP945
Read More
28 Feb 2023
ACCENT Trial Recruitment Progress | Cohort 2 filled
Read More
13 Feb 2023
Women in Science | Q&A with Dr Terrie-Anne Cock, Head of Translational Biology
Read More
09 Feb 2023
35th Annual Lorne Cancer Conference, 9-11 February 2023
Read More
06 Feb 2023
Channel 9 News | 3 February 2023
Read More
06 Feb 2023
The Courier Mail | New hope for advanced pancreatic cancer patients in clinical trials
Read More
06 Feb 2023
ABC Media Coverage | Pancreatic cancer clinical trial opens in Queensland, offering hope to patients
Read More
01 Feb 2023
First Patient Recruited to Cohort 2 of ACCENT Trial in Pancreatic Cancer
Read More
30 Jan 2023
PROACTIVE INTERVIEW | Dr Chris Burns
Read More
11 Jan 2023
Dose Escalation Approved in ACCENT Clinical Trial of AMP945
Read More
08 Dec 2022
Meet the CEO | Dr Chris Burns
Read More
29 Nov 2022
ACCENT Trial Recruitment Progress
Read More
03 Oct 2022
AMP886 Activity in Acute Myeloid Leukemia (AML)
Read More
28 Sep 2022
Stockhead Investor Guide
Read More
18 Aug 2022
Channel 9 | Clinical Trial Recruitment
Read More
18 Aug 2022
The Australian | Drug to tear down tumour defences
Read More
1
2
3
4
5